Sponsored by Medidata, a Dassault Systèmes company
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness) is the industry’s first fully decentralized clinical megatrial (DCT) and one of the largest DCTs to date. A pragmatic, patient-centered, randomized trial, the goal of the study was to determine the optimal aspirin dosage for Americans living with heart disease.
Our webinar will cover:
• ADAPTABLE’s patient-centric design with an emphasis on extensive patient input, recruitment of diverse participants, and use of novel technologies reduced costs while ensuring reliable results, thus proving the many benefits that DCTs can provide to study sponsors, researchers, and patients.
• How the innovative project combined the expertise of academic and industry partners, nascent technology owned by Medidata and a patient-centered research network to prove DCTs can produce valuable information that aids doctors, patients and their caregivers in making real-world medical decisions.
• We will review how this study was the springboard to driving the adoption of DCTs and the development of new innovative technologies to increase patient safety, comprehensive data collection, and operational efficiencies.
Associate Professor of Medicine /Cardiology at Duke University Health System
Dr. Schuyler Jones is an interventional cardiologist and his clinical interests include peripheral artery disease, coronary artery disease, and percutaneous coronary intervention. He currently serves as the Director of the Duke University Cardiac...
Senior Director, Advisory & Enablement Services, Medidata, a Dassault Systèmes company
Holly Robertson is the Sr. Director of Advisory & Enablement Services within the Patient Cloud team at Medidata Solutions, with over 20 years of experience in pre-clinical and clinical research. Dr. Robertson obtained her PhD in Pharmacology from...
Michael is a Managing Partner of Medidata’s Patient Cloud solution sales team, providing leadership and subject matter expertise in decentralized clinical trials and patient centric technologies. Over the last decade, Michael has worked...